- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
AML | Clinical
Future Research Aims to Examine Blocking STAT3 in Acute Myeloid Leukemia
August 02, 2022
Marcin Kortylewski, PhD, discusses what research he believes is next to come in the acute myeloid leukemia space.
Discussing Therapeutic Options For Patients With AML
July 15, 2022
Siddhartha Mukherjee, MD, explains the current golden standard for frontline treatment of patients with acute myeloid leukemia.
GFH009 Demonstrate Early Efficacy in Relapsed/Refractory Lymphoma and AML
June 28, 2022
In a phase 1 clinical trial, treatment with GFH009 showed early signal s of efficacy in patients with advanced relapsed or refractory lymphoma and acute myeloid leukemia.
Gilteritinib and Prior Midostaurin/Sorafenib Aids Clinical Response in Patients with FLT3-Mutated AML
June 27, 2022
Gilteritinib monotherapy reacts favorably and led to higher rates of composite complete remissions in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia who received prior midostaurin or sorafenib.
Examining the Role of Blocking STAT3 in AML
June 14, 2022
Marcin Kortylewski, PhD, discusses some of the goals and findings of his research on blocking STAT3 in acute myeloid leukemia cells.
Magrolimab Plus Azacitidine Treatment Correlates With Manageable Anemia in High-Risk MDS, AML
June 04, 2022
According to , results from a phase 1 study support that on-target magrolimab-mediated anemia is manageable in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia.
BTX-1188 Undergoing Evaluation in AML, Solid Tumors After Showing Promise in Preclinical Data
June 04, 2022
BTX-1188 could prevent systemic inflammatory dose-limiting toxicities that are usually attributed to pure GSPT1 degradation due to its immunomodulatory properties from the IKZF1/3 degradation.
Ivosidenib/Azacitidine Combination Shows Clinical Benefit in IDH1-Mutant AML
June 04, 2022
Phase 3 AGILE results show that ivosidenib plus azacitidine has clinical activity in IDH1-mutant acute myeloid leukemia.
FDA Approves Ivosidenib Plus Azacitidine for Previously Untreated IDH1-Mutated AML
May 25, 2022
The FDA has granted approval for ivosidenib tablets as treatment for patients with previously untreated IDH1-mutated acute myeloid leukemia.
Managing Outcomes of Patients With TP53-Mutant AML and MDS
May 24, 2022
Melhem Solh, MD, discussed how the post transplantation outcomes for patients with MDS and AML with the TP53 gene mutation have changed to what it is today.